Sustained activation and tumor targeting of NKT cells using a CD1d–anti-HER2–scFv fusion protein induce antitumor effects in mice
J. Clin. Invest. Kathrin Stirnemann, et al. 118:994 doi:10.1172/JCI33249 [Go to this article.]

Figure 3
In vivo antitumor activity and HER2 dependency in a precoating experiment. (A) Comparison of 2 different read-out methods for counting lung tumor colonies induced by the i.v. injection of B16 F10 melanoma cells in 2 representative mice (1 and 2): counting of nodules (upper panels) versus the use of ImageJ k-means clustering algorithm program to integrate the black surface of melanin-loaded nodules and to express the result as percent of black surface over total lung surface (lower panels). Original magnification, ×6.3. (B and C) Precoating experiment. B16-HER2 (B) and B16 wt cells (C) were precoated for 1 h with equimolar amounts of αGalCer (0.4 μg/ml), αGalCer/sCD1d–anti-HER2 fusion (40 μg/ml), or Herceptin (10 μg/ml). With or without a previous wash, cells were injected i.v. in C57BL/6 mice. Lung metastases were analyzed 3 weeks after graft as described in A. Results are expressed as percent of black surface of total lung surface and represent the mean ± SD of 5 mice per group of 3 independent experiments. *P < 0.005 compared with PBS control.